复宏汉霖PD-L1 ADC启动全球II/III期关键研究

医药魔方Info03-11

3月10日，美国临床试验收录网站显示，复宏汉霖启动了HLX43治疗鳞状非小细胞肺癌（NSCLC）的II/III期研究。这是该药物启动的首项II/III期临床试验。HLX43是复宏汉霖基于宜联生物技术平台开发的一款PD-L1 ADC，其有效载荷为拓扑异构酶I抑制剂，DAR值为8。临床前研究显示，HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中展现出治疗潜力，且...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618692484?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-11 12:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2618692484","market":"hk","top_or_hot":-1,"title":"复宏汉霖PD-L1 ADC启动全球II/III期关键研究","media":"医药魔方Info","content":"<div>\n<p>3月10日，美国临床试验收录网站显示，复宏汉霖启动了HLX43治疗鳞状非小细胞肺癌（NSCLC）的II/III期研究。这是该药物启动的首项II/III期临床试验。HLX43是复宏汉霖基于宜联生物技术平台开发的一款PD-L1 ADC，其有效载荷为拓扑异构酶I抑制剂，DAR值为8。临床前研究显示，HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中展现出治疗潜力，且...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖PD-L1 ADC启动全球II/III期关键研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖PD-L1 ADC启动全球II/III期关键研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 12:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b><strong>医药魔方Info</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月10日，美国临床试验收录网站显示，复宏汉霖启动了HLX43治疗鳞状非小细胞肺癌（NSCLC）的II/III期研究。这是该药物启动的首项II/III期临床试验。HLX43是复宏汉霖基于宜联生物技术平台开发的一款PD-L1 ADC，其有效载荷为拓扑异构酶I抑制剂，DAR值为8。临床前研究显示，HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中展现出治疗潜力，且...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b","article_id":"2618692484","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618692484","pubTimestamp":1773203156,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月10日，美国临床试验收录网站显示，复宏汉霖启动了HLX43治疗鳞状非小细胞肺癌的II/III期研究。这是该药物启动的首项II/III期临床试验。HLX43是复宏汉霖基于宜联生物技术平台开发的一款PD-L1 ADC，其有效载荷为拓扑异构酶I抑制剂，DAR值为8。临床前研究显示，HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中展现出治疗潜力，且耐受性良好。2025年11月，复宏汉霖公布了HLX43-FIH101及HLX43-NSCLC201两项临床研究的合并分析数据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","02696":"复宏汉霖","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC"},"translate_title":"Henlius PD-L1 ADC initiates global phase II/III pivotal study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5},"content_text":"3月10日，美国临床试验收录网站显示，复宏汉霖启动了HLX43治疗鳞状非小细胞肺癌（NSCLC）的II/III期研究。这是该药物启动的首项II/III期临床试验。HLX43是复宏汉霖基于宜联生物技术平台开发的一款PD-L1 ADC，其有效载荷为拓扑异构酶I抑制剂，DAR值为8。临床前研究显示，HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中展现出治疗潜力，且耐受性良好。该II/III期研究是一项随机、开放标签、多中心、全球性临床试验（n=671），旨在评估HLX43单药（静脉注射，每3周1次）或联合EGFR单抗HLX07（静脉注射，每3周1次）对比多西他赛（静脉注射，每3周1次）治疗既往经一线治疗失败的晚期或转移性鳞状NSCLC患者的有效性和安全性。研究的主要终点是第24个月的总生存期（OS）和无进展生存期（PFS）。2025年11月，复宏汉霖公布了HLX43-FIH101及HLX43-NSCLC201两项临床研究的合并分析数据。截至2025年10月22日，两项研究共纳入174例晚期NSCLC患者，其中89例接受2mg/kg HLX43治疗，85例接受2.5mg/kg HLX43治疗。经研究者评估，在鳞状NSCLC患者（2mg/kg，n=33）中，客观缓解率（ORR）达33.3%，疾病控制率（DCR）为75.8%；在非鳞状NSCLC患者（2.5mg/kg，n=35，包括EGFR野生型及EGFR突变型）中，ORR提升至48.6%，DCR高达94.3%。在接受过多西他赛治疗的三线及后线鳞状NSCLC患者（2mg/kg，n=13）中，ORR达38.5%，DCR为84.6%，提示HLX43在多西他赛治疗失败的肺鳞癌人群中的重要潜力。此外，在PD-L1阴性（TPS＜1%，n=43）患者群体中，ORR和DCR分别达到39.5%和86.0%，提示HLX43疗效不受PD-L1表达限制，有望覆盖更广泛的患者群。推荐阅读JPM2026 | 复宏汉霖：2030年前超20款产品全球上市ORR达到70%！复宏汉霖PD-L1 ADC首个II期研究公开WCLC 2025 | 值得关注的国产肺癌新药国产ADC炫技ASCO 2025Copyright © 2026 PHARMCUBE. All Rights Reserved.免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618692484","isCrawlerRequest":true}